Publication
Comparative RNA-Sequencing Analysis Benefits a Pediatric Patient With Relapsed Cancer.
Authors not recorded
JCO Precis Oncol2018PMID 31372595PMC6675034stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerSarcomacivic_curation1.00
- drugRuxolitinibcivic_curation1.00
- geneJAK1civic_curation1.00
- variantJAK1 OVEREXPRESSIONcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 31372595
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| JAK1 OVEREXPRESSION1 | ||||||||
| Ruxolitinib | Sarcoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID7852Sequencing of an 8-year old patient diagnosed with a left tentorial-based CNS sarcoma discovered an EWSR1-ATF fusion and IL6 and JAK1 overexpression. Patient was treated with ruxolitinib based on over… (full text at CIViC) PMID 31372595 · Newton et al., 2018 · Open in CIViC | civic |